Pirtobrutinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), G-BA (Germany) and HIRA (South Korea), among others, recommended or restricted pirtobrutinib, while AOTMIT (Poland) and NYE METODER (Norway) did not recommend it.
The record spans 2.3 years, opening at CIPM (Spain) on 22 May 2024 and running to 30 Sep 2026.
HAS (France) changed its position: recommended on 10 Sep 2025, not recommended by 5 Nov 2025.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for pirtobrutinib, 1 submission was never made — an outcome set by the company rather than the assessor.
The file is active: 19 of 20 records date from 2023 or later.
4 distinct indication wordings are recorded for pirtobrutinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 20 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
CIPM (Spain) was first to assess pirtobrutinib, on 22 May 2024; NICE (England) did not open a file until 1 Jul 2026 — a moderate spread of 2.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 9 of 19 dated records fall in 2026 alone.
5 of the 14 agencies here assessed pirtobrutinib more than once, CIPM (Spain) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
pirtobrutinib has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for pirtobrutinib reads 5 not recommended, 5 recommended, 2 restricted and 2 other, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NICE (England) | 1 Jul 2026 | NICE TA1173 | published appraisal | source |
| PBAC (Australia) | 2026 | Chronic lymphocytic leukaemia (CLL) | Small lymphocytic lymphoma (SLL) | Not applicable | source |
| AWMSG (Wales) | 5 Jun 2026 | Treatment for relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor | excluded, NICE appraised | source |
| AOTMIT (Poland) | 30 Apr 2026 | programu lekowego B.12.FM. „Leczenie chorych na chłoniaki B-komórkowe (ICD-10: C82, C83, C85) | recommendation issued | source |
| CIPM (Spain) | 25 Mar 2026 | Indicaciones terapéuticas autorizadas: Jaypirca en monoterapia está indicado para el tratamiento de pacientes adultos co… | not financed by the SNS · art. 92 d | source |
15 further decisions for pirtobrutinib, across 11 agencies, are not shown here. They include the most recent record on file, 30 Sep 2026 from TLV (Sweden); its outcome is in the subscriber dataset. They link to 14 further source documents.
Related molecules
- acalabrutinib — divergent outcome (not recommended vs recommended) on a shared indication
- ibrutinib — divergent outcome (not recommended vs recommended) on a shared indication
- idelalisib — divergent outcome (not recommended vs recommended) on a shared indication
- ripretinib — same ATC class L01 — Antineoplastics
- idecabtagene vicleucel — same ATC class L01 — Antineoplastics
- capivasertib — also decided by TLV in 2026Q3
Coverage: 20 decisions for pirtobrutinib from 14 agencies, 2024 to 2026. Data to 7 Sep 2026. ATC class L01 — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.